HAWTHORNE, N.Y. and VERNON HILLS, Ill., July 31, 2008 (PRIME NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) (Pink Sheets:TAROF) and NextWave Pharmaceuticals, Inc. (“NextWave”) today announced that Taro’s U.S. subsidiary (“Taro USA”) and NextWave have entered into an agreement to co-promote OVIDE(r) (malathion) Lotion, 0.5% (“OVIDE”) in the United States.
